Latest News and Press Releases
Want to stay updated on the latest news?
-
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial...
-
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - ...
-
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept....
-
Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in...
-
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
-
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...